15 February 2024

Enhancing drug development for paediatric pulmonary hypertension: an integrative perspective

Our monthly webinar series, PVRI 2024 Digital, continued on February 14 2024, with a session sponsored by the our Innovative Drug Development Initiative (IDDI) Paediatric Workstream. The webinar featured talks from four highly respected speakers on enhancing drug development for paediatric pulmonary hypertension (PH). Get the details of the full series here.


  • Clinical challenges in developing drug therapies for children with PH Rolf Berger, Beatrix Children’s Hospital, University Medical Center Groningen, Netherlands 
  • Challenges related to drug approval for children with PH – regulatory perspective Christine Garnett, U.S. Food and Drug Administration
  • Challenges facing pharmaceuticals in drug development for paediatric PH Sylvia Nikkho, Bayer Pharmaceuticals, Germany & PVRI-IDDI Co-leader
  • Utility of paediatric registries for the characterization of pulmonary hypertensive phenotypes Maria Jesus del Cerro, Ramon y Cajal Hospital, Spain

Moderated by Steve Abman, University of Colorado, USA and Pegah Nowbakht, VectivBio now part of Ironwood, Switzerland

Comments (0)

Our research platform is the world.

Through worldwide collaboration, we can begin to answer the question of a global disease.

Join the PVRI